Retreatment Strategies for Patients Failing First-Line Therapy
Source: Advanced Topics in Hepatitis C Management: Tools for Nurse Practitioners and Physician Assistants

Module

HoChong Gilles, RN, MS, FNP, reviews clinical management options for patients with chronic HCV infection who fail interferon-based therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify causes of nonresponse and relapse to hepatitis C virus (HCV) therapy
  • Describe definitions of response during HCV therapy and key time points for monitoring response to treatment
  • Discuss diagnosis and management of common adverse effects of HCV therapy and strategies for monitoring patient adherence
  • Recall strategies for selecting optimal treatment for patients based on their baseline factors and previous course of therapy

Topics covered include:

  • Introduction
  • Treatment Response Patterns
  • Factors Contributing to Treatment Failure
  • Comorbidities as Predictors of Nonresponse
  • Other Factors Associated With Nonresponse
  • Assessing Factors Related to Nonresponse Before Retreatment
  • Retreatment Options in Nonresponders and Relapsers
  • Summary: Implications for Clinical Practice
 

Program Directors

  • Michael W. Fried
    MD

Faculty

  • HoChong Gilles
    RN, MS, FNP

Credit Information

  • Release Date:
    June 28, 2007
  • Expiration Date:
    June 27, 2008
  • Physicians:
    maximum of 1.5 AMA PRA Category 1 Credits
  • Registered Nurses:
    1.5 Nursing contact hours
  • Physician Assistants:
    maximum of 1.5 hours of AAPA Category I (Preapproved) credits
  • When Should Patients on the Liver Transplant Waitlist Receive HCV Therapy?

    John Roberts MD - 4/24/2015    1 comment / Last Comment: 4/30/2015
    Now that highly tolerable, highly effective HCV treatments are available, treatment in the pretransplant setting is a viable approach for many patients currently on the waitlist. Does this approach have a downside?
  • Using Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 or 24 Weeks, With or Without Ribavirin?

    Paul Y. Kwo MD - 4/8/2015    2 comments / Last Comment: 4/24/2015
    Until more data are available on the use of the 3-DAA regimen in genotype 1 cirrhotic, treatment-experienced patients, I prefer to err on the side of caution to maximize opportunity for achieving SVR.
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015    2 comments / Last Comment: 5/19/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • Using Ledipasvir/Sofosbuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 Weeks With Ribavirin or 24 Weeks Without?

    Ira M. Jacobson MD - 3/23/2015    4 comments / Last Comment: 4/20/2015
    Although new data suggest comparable efficacy of ledipasvir/sofosbuvir with ribavirin for 12 weeks vs 24 weeks without ribavirin in genotype 1 cirrhotic, treatment-experienced patients, I am not convinced that shortening treatment is the best approach.
  • HCV Treatment in Liver Transplantation Recipients: My Take on the Latest HCV Guidance

    Nezam H. Afdhal MD, FRCPI - 4/7/2015    1 comment / Last Comment: 4/13/2015
    In starting HCV treatment after liver transplant, how soon is soon enough?